Recombinant Human beta Synuclein protein is a Human Full Length protein, in the 1 to 134 aa range, expressed in Escherichia coli, with >95% purity and suitable for WB, SDS-PAGE.
>95% SDS-PAGE
Escherichia coli
Tag free
WB, SDS-PAGE
No
M D V F M K G L S M A K E G V V A A A E K T K Q G V T E A A E K T K E G V L Y V G S K T R E G V V Q G V A S V A E K T K E Q A S H L G G A V F S G A G N I A A A T G L V K R E E F P T D L K P E E V A Q E A A E E P L I E P L M E P E G E S Y E D P P Q E E Y Q E Y E P E A
Application | Reactivity | Dilution info | Notes |
---|---|---|---|
Application WB | Reactivity Reacts | Dilution info - | Notes ab48853 can be used as a WB positive control in conjunction with ab25650. |
Application SDS-PAGE | Reactivity Reacts | Dilution info - | Notes Predicted molecular weight 14 kda; molecular size on SDS-PAGE will be higher. |
Select an associated product type
Non-amyloid component of senile plaques found in Alzheimer disease. Could act as a regulator of SNCA aggregation process. Protects neurons from staurosporine and 6-hydroxy dopamine (6OHDA)-stimulated caspase activation in a p53/TP53-dependent manner. Contributes to restore the SNCA anti-apoptotic function abolished by 6OHDA. Not found in the Lewy bodies associated with Parkinson disease.
Beta-synuclein, SNCB
Recombinant Human beta Synuclein protein is a Human Full Length protein, in the 1 to 134 aa range, expressed in Escherichia coli, with >95% purity and suitable for WB, SDS-PAGE.
>95% SDS-PAGE
Escherichia coli
Tag free
WB, SDS-PAGE
No
No
Human
pH: 7.5
Constituents: 0.58% Sodium chloride, 0.316% Tris HCl, 0.0095% Magnesium chloride
M D V F M K G L S M A K E G V V A A A E K T K Q G V T E A A E K T K E G V L Y V G S K T R E G V V Q G V A S V A E K T K E Q A S H L G G A V F S G A G N I A A A T G L V K R E E F P T D L K P E E V A Q E A A E E P L I E P L M E P E G E S Y E D P P Q E E Y Q E Y E P E A
Full Length
1 to 134
Recombinant
Liquid
Non-amyloid component of senile plaques found in Alzheimer disease. Could act as a regulator of SNCA aggregation process. Protects neurons from staurosporine and 6-hydroxy dopamine (6OHDA)-stimulated caspase activation in a p53/TP53-dependent manner. Contributes to restore the SNCA anti-apoptotic function abolished by 6OHDA. Not found in the Lewy bodies associated with Parkinson disease.
Belongs to the synuclein family.
Phosphorylated. Phosphorylation by G-protein coupled receptor kinases (GRK) is more efficient than phosphorylation by CK1, CK2 and CaM-kinase II.
Blue Ice
-20°C
-20°C
Upon delivery aliquot
Avoid freeze / thaw cycle
This supplementary information is collated from multiple sources and compiled automatically.
Beta-synuclein also known as β-synuclein or SNCB is a protein that plays a role in the nervous system. It is a small protein with a molecular weight around 14 kDa. Predominantly beta-synuclein is found in presynaptic terminals of neurons in the central nervous system including the brain and spinal cord. This protein shares significant amino acid sequence identity with alpha-synuclein and gamma-synuclein comprising the synuclein family. It acts as a modulator of neuronal and synaptic function influencing the dynamics of neurotransmitter release.
Beta-synuclein contributes to cellular homeostasis and synaptic integrity. It is not typically found as part of a larger protein complex like its relative alpha-synuclein which forms toxic aggregates. Instead beta-synuclein exhibits neuroprotective properties helping maintain neuronal health. It possibly regulates synaptic vesicle cycling and mitigates levels of alpha-synuclein aggregation. Research suggests that loss of beta-synuclein function might disrupt synaptic stability leading to neurological issues.
Beta-synuclein engages in synaptic function and plasticity. It participates in pathways related to neurotransmitter release and synaptic vesicle trafficking. Beta-synuclein is connected to calcium/calmodulin-dependent protein kinase II (CaMKII) pathways. This interaction supports beta-synuclein's regulatory impact on synaptic vesicle dynamics negatively modulating the aggregation-prone behaviors seen in alpha-synuclein during synucleinopathies.
Beta-synuclein plays a role in neurodegenerative diseases like Parkinson’s disease and dementia with Lewy bodies. Research highlights its relationship with these conditions due to its interaction with alpha-synuclein known to form pathological aggregates and contribute to disease progression. Beta-synuclein's modulation of alpha-synuclein activity can impact the development and progression of these disorders. There is ongoing interest in its potential protective role suggesting it might be leveraged in therapeutic strategies against synucleinopathy-related diseases.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
ab48853 in 15%SDS-PAGE.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com